Bone Health Should Be an Important Concern in the Care of Patients Affected by 21 Hydroxylase Deficiency by Bachelot, Anne et al.
Hindawi Publishing Corporation
International Journal of Pediatric Endocrinology
Volume 2010, Article ID 326275, 7 pages
doi:10.1155/2010/326275
Review Article
Bone Health ShouldBe an Important Concern in the Care of
Patients Affectedby 21 Hydroxylase Deﬁciency
AnneBachelot,1,2 Zeina Chakhtoura,1,2 DinaneSamara-Boustani,3 J´ erome Dulon,1,2
Philippe Touraine,1,2 andMichelPolak3
1AP-HP, Department of Endocrinology and Reproductive Medicine, Groupe Hospitalier Piti´ e-Salp´ etri` ere,
47-83 boulevard de l’Hˆ opital, 75013 Paris Cedex 13, France
2Centre de R´ ef´ erence des Maladies Endocriniennes Rares de la Croissance, Groupe Hospitalier Piti´ e-Salp´ etri` ere,
47-83 boulevard de l’Hˆ opital, 75013 Paris Cedex 13, France
3AP-HP, Department of Pediatric Endocrinology and Gynecology, Hˆ opital Necker-Enfants Malades,
149 rue de S` evres, 75015 Paris, France
Correspondence should be addressed to Philippe Touraine, philippe.touraine@psl.aphp.fr and
Michel Polak, michel.polak@nck.aphp.fr
Received 6 April 2010; Accepted 8 July 2010
Academic Editor: John Fuqua
Copyright © 2010 Anne Bachelot et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Osteoporosis has been an understandable concern for children and adult patients with congenital adrenal hyperplasia (CAH) who
may receive or have received supraphysiological doses of glucocorticoids. Some previous reports on bone mineral density (BMD)
in adult CAH patients showed no signiﬁcant diﬀerences in BMD between patients with CAH and controls, but others have found
lower BMD in CAH patients. In reports documenting the BMD reduction, this outcome has been attributed to an accumulated
eﬀect of prolonged exposure to excess glucocorticoids during infancy and childhood. We recently conducted a trial to establish the
role of the total cumulative glucocorticoid dose on BMD. We established for the ﬁrst time that there was a negative relationship
between total cumulative glucocorticoid dose and lumbar and femoral BMD. Women might beneﬁt from the preserving eﬀect of
estrogens compared to men. BMI (Body Mass Index) also appeared to protect patients from bone loss. In light of this, physicians
shouldbearinmindthepotentialconsequencesofglucocorticoidsonboneandthereforeadjustthetreatmentandimproveclinical
and biological surveillance from infancy. Furthermore, preventive measures against corticosteroid-induced osteoporosis should be
discussed right from the beginning of glucocorticoid therapy.
1.Introduction
Congenital adrenal hyperplasia (CAH, MIM 201910)
describes a group of inherited autosomal recessive disorders
characterized by enzyme defects in the steroidogenic path-
ways that lead to the biosynthesis of cortisol, aldosterone,
and androgens. Many diﬀerent mutations of the CYP21 gene
have been identiﬁed causing varying degrees of impairment
of 21-hydroxylase activity that result in a spectrum of disease
expression [1]. Most patients are compound heterozygotes,
and the clinical phenotype is generally related to the less
severely mutated allele and, consequently, to the residual 21
hydroxylase activity.
Indeed, CAH is classiﬁed according to symptoms and
signs and to age of presentation. The clinical phenotype is
typically classiﬁed as classic for the severe form, or non-
classic (NCF) for the mild or late-onset form. Classic CAH
is subclassiﬁed as salt-wasting (SW) or simple-virilizing
(SV) forms, reﬂecting the degree of aldosterone deﬁciency.
Current treatment is intended to reduce excessive ACTH
and consequent increase in androgen production by substi-
tuting for deﬁcient cortisol synthesis and, when necessary,
mineralocorticoid substitution. During childhood, the main
aims of the medical treatment of CAH secondary to 21-
hydroxylase are to prevent salt loss and virilization, to
achieve normal stature, and to undergo normal puberty [2].
Undertreatment exposes the patient to the risk of adrenal
crisis and allows increased adrenal androgen production,
with consequent advancement of bone age and loss of
growth potential. Overtreatment, however, results in growth2 International Journal of Pediatric Endocrinology
retardation, truncal obesity, and osteopaenia, through the
eﬀects of steroids on growth hormone secretion and bone
metabolism.Inadulthood,theaimsofthemedicaltreatment
are to substitute cortisol and, when necessary, aldosterone
deﬁciency, to ensure normal fertility, and to avoid the long-
term consequences of glucocorticoid use. In such an inter-
vention,thereisanarrowtherapeuticwindowthroughwhich
the intended results can be achieved. Indeed, other states,
as Cushing’s syndrome and pharmacological glucocorticoid
therapy, can aﬀect peak bone mass in growing individ-
uals and generate osteoporosis via multiple mechanisms,
resulting in increased bone resorption and suppression of
bone formation. Chronic glucocorticoid therapy is known
to generate bone loss in many ways: a direct suppression
of osteoblastic activity [3] and an inhibition of digestive
calcium absorption with secondary hyperparathyroidism
and increased bone resorption by osteoclasts [4]. Gluco-
corticoids also lead to an inhibition of intestinal calcium
absorptionandanincreaseofrenalcalciumexcretionleading
to secondary hyperparathyroidism [5].
2. Bone MineralDensity Studies in Children
andAdults with 21 HydroxylaseDeﬁciency:
Results andLimitations
Based on these ﬁndings, many studies have attempted to
analyse bone mineralization status in patients with 21-
hydroxylase deﬁciency, with the precise goal of identifying
bone demineralization (Table 1). Some studies reported
no signiﬁcant diﬀerences in bone mineral density (BMD)
between patients and controls as measured by DXA [6–11]
whereasothersfoundlowerBMDorbonemineralcontentin
all or some subpopulations of CAH patients [12–21]. These
contradictory results may be explained by heterogeneous
populations and methods, as the reports diﬀer with respect
to age selections and glucocorticoid regimens. Indeed, a
couple of studies included pre- and postpubertal patients
who had not yet reached their ﬁnal height, while others
sought to compare BMD with average glucocorticoid dose,
at the time of the study.
The age of the patients is an important confounding
factor in the study of BMD in CAH patients. Only four
studieshaveevaluatedBMDinprepubertalandinadolescent
patients with the salt-wasting form of CAH [7, 14, 15, 21].
Gussiny´ e et al. studied 16 children, 1.5 to 8.3 years old,
17 young adults, 17 to 28 years old, and a control group
[7]. The average doses of hydrocortisone (mg/m2 body
surface/day) received from diagnosis in the neonatal period
to BMD evaluation were 21.2 ± 2.2 and 22.3 ± 2.6, respec-
tively. Mean BMD Z score values did not show statistically
signiﬁcant diﬀerences with age- and sex-matched controls.
Nevertheless, 4 of these children have BMD less than −1
SD. Cameron et al. concluded also that replacement therapy
with glucocorticoid and mineralocorticoid hormones were
not deleterious in terms of general bone mineralization in
21 CAH patients (aged 8–32yr) [14]. Paganini et al. showed
on 50 CAH patients (23 males, 27 females), aged 1–28 years,
that an impairment in bone growth and mineralization may
Table 1: Summary of literature involving adult bone mineral
density studies in CAH patients.
References
Number of
patients
(male/female)
Age
(yrs) Results on BMD
Guo et al. [6] 6/5 19–65 Normal
Gussiny´ ee ta l .[ 7] 23/10 1–28 Normal
Mora et al. [8] 11/19 17±2N o r m a l
Stikkelbroeck et al.
[9] 15/15 17–25 Normal
Girgis and Winter
[10] 12/16 4.9–22 Normal
Christiansen et al.
[11] 10/8 18–33 Normal
Jaaskelainen and
Voutilainen [12] 16/16 16–52 Decreased
Hagenfeldt et al.
[13] 0/13 20–29 Normal total BMD,
reduced spine BMD
Cameron et al. [14] 13/8 8–32 Normal in women
Decreased in men
Paganini et al. [15] 23/27 1–28 Decreased
De Almeida Freire
et al. [16] 17/28 5–16 Decreased
King et al. [17] 0/26 21–71 Decreased
Sciannamblo et al.
[18] 15/15 16–30 Decreased
Bachelot et al. [19] 9/36 18–47 Decreased
Falhammar [20] 0/61 18–63 Decreased
Zimmermann [21] 10/18 5–39 Decreased
be found in young adults but not in children aﬀected by the
classical form [15]. Nevertheless, Zimmermann et al. [21]
found reduced Z-score (≤− 1 SD) in 60.8% of the patients,
with a percentage of 61.5% in the SW form (8/13 patients,
age 5 to 17 years), and 60% in the SV form (9/15 patients,
age 5.1 to 39 years). Conversely, only four studies included
patients older than 50 years [6, 12, 17, 20], among which
two found BMD alteration in CAH patients, that tends to be
correlated with hydrocortisone dose.
DXA measurements of BMD depict areal bone density,
and bone thickness is not considered. This can lead to an
underestimate of BMD in small and an overestimate in
large bones. A recent study has calculated BMAD (g/cm3)
with formulas reported to reduce the confounding eﬀect
of bone size [20]. Even with this approach, bone density
was signiﬁcantly reduced in their patients at all measured
sites, indicating that the diﬀerences found were real and
not only due to measurement bias. This is also supported
by the ﬁnding in this study that the patients and controls
with normal height (160–169cm) had the same diﬀerences
in BMD, as was found in the entire study population
[20]. Still, in very short individuals, an overestimation of
osteopenia/osteoporosis may occur with conventional DXA
measurements. However, DXA remains a useful tool for fol-
lowup in the management of individual patients. Of interest,International Journal of Pediatric Endocrinology 3
short stature by itself observed in some CAH patients might
also be a risk factor for fractures, as small bones may be less
resistant to mechanic restraints. Conversely, overweightness,
obesity, and hyperandrogenism seem to be protective on
BMD [19].
In studies showing alteration of BMD, Z-score, or T-
score, it has been showed to be less than −2,5 SD in
0% to 18% of the CAH patients and between −2,5 and
−1,0 SD in 13% to 52% of the patients [12, 16, 17,
19]. This low BMD might be explained by glucocorticoid
overtreatment itself or by suppression of androgen levels
due to glucocorticoid overtreatment, and/or by premature
puberty and hypogonadism induced by undertreatment or
some antiandrogen treatment. However, few studies have
extensively studied the link between BMD alteration and
glucocorticoid dose [12–14, 17, 19, 21], as it is possible that
androgen deﬁciency per se may be of importance for the
development of low BMD, in addition to the direct catabolic
eﬀects of glucocorticoids on bone. This may be especially
important in postmenopausal women.
In reports documenting the BMD reduction, this out-
come has been attributed to an accumulated eﬀect of
prolonged exposure to excess glucocorticoids during infancy
and childhood. The role of each of these factors has been
evaluated in a number of studies published over the last
decade, often with conﬂicting results. Most studies are ret-
rospective, include mixed populations (children and young
adults), have a small sample size, and are unable to precisely
assess the eﬀect of cumulative glucocorticoids doses. For
example, Jaaskelainen and Voutilainen [12] chose a current
and mean long-term glucocorticoid dose, Hagenfeldt et al.
[13], an index of accumulated postmenarchal glucocorticoid
medication, Sciannamblo et al. [18], the median of the last
seven years of treatment, and Stikkelbroeck et al. [9], a
cumulative dose which was calculated exactly over 0.5, 2, and
5yr preceding the investigation. Thus, some authors do not
ﬁnd a correlation of BMD with the present glucocorticoid
dose [18], with the cumulative dose calculated for the last 2
years [6], or for the last 7 years [18], with the duration of
treatment [6], or with the age of treatment start [6].
3. Bone MineralDensity inYoungAdults with
21 HydroxylaseDeﬁciency, inRelation to
Cumulative Dose of Glucocorticoid from the
Start of the Treatment
To resolve this issue, we hypothesized that there could be a
negative role of the total cumulative glucocorticoid (TCG)
dose on BMD. We therefore collected the data of the daily
dose of glucocorticoid received from the time of diagnosis in
earlyinfancyuptothetimeofinclusioninourstudy[22].We
considered adult patients >16 years old with classical CAH
and nonclassical CAH that had been revealed by precocious
puberty, and who had been continuously monitored and
treated since childhood. Thirty eight adult patients suﬀering
from CAH due to 21-hydroxylase deﬁciency and treated
since early infancy in pediatric centers were included in
our study. Twenty-four of them (63.2%) have the salt-
wasting form (SW) (14 women, 10 men), 5 the simple
virilizing form (SV) (13.1%, women only in this group),
and 9 the nonclassical form revealed by precocious puberty
(23.7%, women only in this group). They had all been on
glucocorticoid treatment since diagnosis in infancy and 23
of them (60.5%) were also receiving mineralocorticoid (9α-
ﬂudrocortisone) during the study. The mean current dose
in growth retarding hydrocortisone equivalents (1mg of
dexamethasone = 16mg of prednisone = 80mg of hydrocor-
tisone) was 16.9 ± 5.5mg/m2/d. Mean daily dose over a year
could be distinguished in three periods: salt-wasters were
treated with 23.8 ± 8.8mg/m2/d the ﬁrst two years of life,
patients with classical (SW and SV) and nonclassical forms
had, respectively, 18.2 ± 4.8 and 12.7 ± 4.1mg/m2/d during
childhood(P<. 001),and20.4 ±6.4and13.8 ±3.0mg/m2/d
during puberty (P = .01). We found a negative eﬀect of
TCG on lumbar and femoral T-scores (Figure 1). Moreover,
we demonstrated the same negative eﬀect with TAG, which
represented the average daily dose of glucocorticoids that
patients received over their entire therapy life-period. In
fact, 44.7% of the participants had bone demineralization
according to WHO criteria, which is superior to a Gaussian
repartition, in which 16% of the general population is
under −1 SD. These results are reinforced by the fact that
patients do not always take their therapy as prescribed,
notably during childhood and adolescence; in other words
real glucocorticoid intakes may be sometimes lower than
those written in ﬁles. Our results are reinforced by Van Staa’s
et al. meta-analysis which underlined a strong correlation
between cumulative dose and loss of BMD, mean daily
dose, and risk of fracture independently of underlying
disease requiring corticotherapy, age, and gender [23]. A
recent study [21] conﬁrmed our results, showing a negative
correlation between mean and cumulative glucocorticoid
dose and treatment duration with BMD.
We found fairly normal pubertal development in boys
(11.6 ± 1.6 years) and girls (10.3 ± 1.8 years) and a mean
age of menarche around 13.6 ± 1.6 years, which had also
been reported by Hughes and Read [24] and Bonﬁg et al.
[25]. We noted low ﬁnal height compared to target height,
consistent with former publications [26–28], while onset-
pubertal height was normal. Height gain was also reported
as poor during pubertal years in studies conducted by
Stikkelbroeck et al. [29]a n dV a nd e rK a m pe ta l .[ 30].
4. Bone Mineral Densityin Relation to
Puberty,Hormonal Status,Glucocorticoid
Treatment, and Height
This underlines the fact that the impact of glucocor-
ticoid/androgen balance is more important than altered
puberty development in this population. Firstly, hyper-
androgenism during infancy due to undertreatment leads
to growth velocity acceleration and a premature closure
of epiphysial plates [14]. Conversely, overtreated children
suﬀer from growth retardation [10, 31]. One may wonder
whether peak bone mass acquired during puberty might be4 International Journal of Pediatric Endocrinology
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Figure 1: T-score regression lines explained by total cumulative
glucocorticoid dose.
aﬀected by this therapy as total pubertal growth diminishes.
Indeed, we underlined that BMD was mostly aﬀected by
theglucocorticoidtherapyduringpuberty.Thiscorroborates
Gussinye’s work in which BMD values of adolescent and
young adult CAH patients were signiﬁcantly lower than
those of the age- and sex-matched controls whereas it did
not diﬀer between prepubertal patients and controls [7].
Secondly, glucocorticoids may lead to osteoporosis [32],
while androgens are known to increase bone formation
markers [33, 34]. Many studies have pointed out that normal
endogenous cortisol production is around 7mg/m2/d in
healthy people [35, 36] whereas clinicians advocate 10 to
15mg/m2/d of exogenous therapy [37], which can bring on
corticosteroid side eﬀects in bones and result in subnormal
androgen levels. In light of this, nonclassical CAH had
better BMD than classical CAH groups, and their TAG were
lower. Similarly with the literature, no correlation was found
between BMD and hormonal parameters, probably because
hormonal concentrations reﬂect a punctual measurement,
whiletheBMDvaluesaretheintegratedresultofalong-term
process.
5. SexualDimorphism for the Impact of
DemineralizationinPatientswith
21 HydroxylaseDeﬁciency
We observed a large discrepancy between lumbar and
femoral T-scores between women and men in this study.
Authors of published papers explained that estrogens have
a more protective action for bone mineralization than
androgen [33, 38], which could contribute to this result,
all the more since the majority of women took exogenous
estrogens. In addition, it appears that adult males with CAH
f a c ead u a lp r o b l e m :( 1 )a d r e n a ls t e r o i do v e r p r o d u c t i o n ,
especially androgen and progesterone which are less protec-
tive on BMD than testosterone, might interfere with FSH
and LH production, resulting in gonadotropin deﬁciency
and consequent small testicular size and lower testosterone
levels [39, 40], and (2) adrenal rests can interfere directly
with the endocrine function of normal testicular tissue in
a mechanical way or by local steroid production. Further-
more,supraphysiologicaldosesofglucocorticoidscaninhibit
gonadotrophic axis and also deprive bone of the protective
role of testosterone. We showed that BMD in women taking
exogenous estrogens were similar compared with those who
were not under estrogen therapy. Nevertheless, we did not
distinguish between diﬀerent hormonal treatments, their
duration, or the periods over which they were administered.
Finally, our population was fairly young at 24.6 ± 5.9
years, the oldest patient being 39. It is recognized that men
and premenopausal women may suﬀer from glucocorticoid-
induced osteoporosis [41, 42], and postmenopausal women
also have a high risk of fracture during corticosteroid
treatment [43].
6. FracturesinPatientswith
21 HydroxylaseDeﬁciency
Osteoporosis is a strong risk factor for fractures, but only
one study has evaluated fractures in CAH patients [20].
This study included 61 women, aged 18–63yr, 27 with salt
wasting, 28 with simple virilizing, and 6 with nonclassical
21-hydroxylase deﬁciency. A total of 61 age-matched women
were controls. Results indicated a higher frequency of frac-
turesinwomenwithCAH.Whenonlyosteoporoticfractures
(vertebrae, wrist, and hip) were considered, the diﬀerence
almostreachedsigniﬁcance(P = .058).Thisisofimportance
for CAH patients, even if this ﬁnding has to be conﬁrmed in
larger studies, which should evaluated diﬀerences in lifestyle
between patients and controls, as the trauma leading to
fractures was not ascertained. This is in accordance with a
studyshowingincreasedriskoffracturesinpatientsreceiving
glucocorticoid therapy, even with low dose [44]. We may
then suppose that aging patients with CAH are at risk of
fracture; therefore, preventive methods might be introduced,
including physical activity and diet-recommendations and
vitamin D supplementation if necessary [45].
7. Bone Turnover Markers in
21 HydroxylaseDeﬁciency
Biochemical markers of bone turnover have also been
partially evaluated in patients with CAH [6, 10, 15, 18, 20],
and literature data are inconclusive. Bone turnover was
found to be lower in patients with CAH than in controls, and
osteocalcin levels correlated positively with growth velocity
and negatively with BMD [6, 10]. Another recent study
showedhigherbone-speciﬁcalkalinephosphatase(ALP)and
serum β-C-telopeptide of type I collagen (CTX) concen-
trations in CAH patients compared with control subjects,International Journal of Pediatric Endocrinology 5
but this did not correlate with the actual glucocorticoid
dose or the mean dose used during the previous 7yrs [18].
The bone resorption marker CTX was recently reevaluated
[20]. It was reduced in the older group of patients both
compared with controls and younger patients. This was not
in accordance with the ﬁndings of Sciannamblo et al. [18]
and of Zimmermann et al. [21] that observed elevated CTX
concentrations in young individuals, some still growing.
The authors concluded that the CAH patients treated for
many years had predominantly low bone formation but also
unexplainedlowboneresorption[46].Regardingtheparam-
eters of bone mineralization, a few patients of the study
by Falhammar et al. exhibited PTH levels above the upper
level of the reference range concomitant with low normal
calcium concentrations, and they were all osteopenic [20].
This can be interpreted as secondary hyperparathyroidism,
likely attributable for the authors to glucocorticoid therapy.
However, the 25-hydroxyvitamin D levels were not assessed
in this study.
Finally, possible role of GH has been assessed. Indeed,
glucocorticoid administration may aﬀect the growth axis
in CAH in several ways. While CAH patients have normal
responses to provocative GH stimulation testing, it has been
suggested that the pattern of GH release changes with the
administration of glucocorticoids [47]. However, normal
IGF-I levels are reported in the majority of studies [30].
Noteworthy in Falhammar et al. study, CAH patients had
higher IGF-I SDS compared with controls and the authors
interpreted this phenomenon as a state of IGF-I resistance
induced by glucocorticoids, and speculate that this could
be a explanation for growth retardation in children on
glucocorticoids.
8. Conclusions
Despitetheseconﬂictingresultsintheliterature,andbecause
some studies showed that young adult patients with the
classical form of CAH have decreased bone density values
compared with healthy controls and that this may put
them at risk of developing osteoporosis early in life, CAH
patients should be considered at risk for osteoporosis and
fracturesandphysicianshavetosystematicallycheckBMDin
CAH adult patients. Furthermore, even if no interventional
therapeutic study exist in CAH patients, preventive measures
against corticosteroid-induced osteoporosis should be dis-
cussed right from the beginning of glucocorticoid therapy.
Osteoporosis prophylaxis such as physical activities and
calcium and vitamin D supplementation should be imple-
mented. Therefore, Vitamin D status should systematically
be determined in CAH patients and calcium and vitamin
D supplementation recommended in patients with vitamin
D deﬁciency and in those receiving high dose of steroids.
The frequency of such measures during adulthood remains
unresolved, and probably depends on the initial result of
the BMD. The results obtained in adults are an incentive
to follow bone mineral density in children, using the right
normative data and expression of the results as Z score.
Adequate calcium and vitamin D intake, in relation to the
age of the child, should also be given. Finally, in accordance
with the literature, optimizing the doses of glucocorticoids
should always be the primary option in CAH patients.
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